Skip to main content

ADC Therapeutics SA (ADCT)

NYSE: ADCT · Delayed Price · USD
28.86 1.10 (3.96%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap2.26B
Revenue (ttm)3,760
Net Income (ttm)-56.07M
Shares Out78.27M
EPS (ttm)-2.67
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume414,230
Open27.68
Previous Close27.76
Day's Range27.53 - 29.08
52-Week Range20.01 - 46.20
Betan/a
Analystsn/a
Price Target43.83 (+51.9%)
Est. Earnings DateNov 2, 2021

About ADCT

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in com...

IndustryCommunications Equipment
IPO DateMay 15, 2020
Employees208
Stock ExchangeNYSE
Ticker SymbolADCT
Full Company Profile

Financial Performance

Financial Statements

News

ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

4 days ago - Business Wire

ADC Therapeutics to Participate in Morgan Stanley's 19th Annual Global Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

1 week ago - Business Wire

ADC Therapeutics Announces Medical Leadership Transition

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

2 weeks ago - Business Wire

ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

3 weeks ago - Business Wire

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Misses Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 16.67% and -34.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti...

1 month ago - Business Wire

ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

1 month ago - Business Wire

ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

2 months ago - Business Wire

ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

2 months ago - Business Wire

Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More

Tuesday's futures were fairly positive after a somewhat mixed start to the week.

3 months ago - 24/7 Wall Street

ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

3 months ago - Business Wire

ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

3 months ago - Business Wire

ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

3 months ago - Business Wire

ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

3 months ago - Business Wire

ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

3 months ago - Business Wire

ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological ...

3 months ago - Business Wire

ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

4 months ago - Business Wire

ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

4 months ago - Business Wire

ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

4 months ago - Business Wire

ADC Therapeutics' ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Pr...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

4 months ago - Business Wire

ADC Therapeutics to Participate in May Investor Conferences

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

4 months ago - Business Wire

ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological...

4 months ago - Business Wire

ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment

ADC Therapeutics SA (NYSE: ADCT) has scored an FDA approval for Zynlonta, formerly known as loncastuximab tesirine, as a solo treatment for adult patients with relapsed or refractory diffuse large B-cel...

4 months ago - Benzinga

ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA™ (loncastuximab tesirine-lpyl) for the tre...

4 months ago - Business Wire

Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer

BOSTON, SHANGHAI & LAUSANNE, Switzerland--(BUSINESS WIRE)--Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the appointm...

5 months ago - Business Wire